Skip to main content

Table 3 Trends of antimicrobial resistance of Gram-positive and Gram-negative bacteria in General Hospital of Tripolis, Greece (2001–2005).

From: Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece

  Number of resistant isolates/total isolates (proportion) within the year
Microorganisms 2001 2002 2003 2004 2005 Total
Gram-positive       
Staphylococcus epidermidis       
Oxacillin* 0/15 (0) 6/15 (40) 7/26 (26.9)    13/56 (23.2)
Gentamicin 2/15 (13.3) 1/15 (6.7) 1/26 (3.8) 0/26 (0) 9/52 (17.3) 13/134 (9.7)
Vancomycin 0/15 (0) 0/15 (0) 0/26(0) 0/26 (0) 0/52 (0) 0/134 (0)
Penicillin     13/26 (50) 40/52 (76.9) 53/78 (67.9)
Staphylococcus aureus       
Oxacillin* 0/6 (0) 5/9 (55.6) 0/14 (0)    5/29 (17.2)
Gentamicin 1/6 (16.7) 1/9 (11.1) 0/14 (0) 3/21 (14.3) 1/18 (5.6) 6/68 (8.8)
Vancomycin 0/6 (0) 0/9 (0) 0/14 (0) 0/21 (0) 0/18 (0) 0/68 (0)
Penicillin     14/21 (66.7) 13/18 (72.2) 27/39 (69)
Streptococcus viridans       
Penicillin    0/1 (0)    0/1 (0)
Vancomycin    0/1 (0)    0/1 (0)
Gram-negative       
Escherichia coli       
Trimethoprim-sulfamethoxazole 8/20 (40) 6/17 (35.2) 6/22 (27.2) 6/22 (27.2) 6/27 (22.2) 32/108 (29.6)
Amikacin 8/20 (40) 4/17 (23.5) 1/22 (4.5) 0/22 (0) 6/27 (22.2) 19/108 (17.6)
Gentamicin 2/20 (10) 4/17 (23.5) 0/22 (0) 0/22 (0) 2/27 (7.4) 8/108 (7.4)
Ampicillin 3/20 (15) 0/17 (0) 6/22 (27.2) 8/22 (36.3) 10/27 (37.0) 27/108 (25.0)
Cefuroxime 0/20 (0) 0/17 (0) 2/22 (9.1) 1/22 (4.5) 6/27 (22.2) 9/108 (8.3)
Pseudomonas aeruginosa       
Amikacin 0/2 (0) 0/3 (0) 0/4 (0) 0/11 (0) 3/9 (33.3) 3/29 (10.3)
Ceftazidime 0/2 (0) 0/3 (0) 0/4 (0) 2/11 (18.2) 2/9 (22.2) 4/29 (13.8)
Ciprofloxacin 1/2 (50) 0/3 (0) 0/4 (0) 4/11 (36.4) 3/9 (33.3) 8/29 (27.6)
Imipenem 0/2 (0) 0/3 (0) 0/4 (0) 0/11 (0) 1/9 (11.1) 1/29 (3.4)
Acinetobacter baumanii       
Amikacin    0/3 (0) 1/2 (50) 0/1 (0) 1/6 (16.7)
Gentamicin    0/3 (0) 0/2 (0) 0/1 (0) 0/6 (0)
Ceftazidime    3/3 (100) 1/2 (50) 0/1 (0) 4/6 (66.7)
Ciprofloxacin    3/3 (100) 2/2 (100) 0/1 (0) 5/6 (83.3)
Imipenem    0/3 (0) 0/2 (0) 1/1 (100) 0/6 (0)
Klebsiella pneumoniae       
Ceftazidime   0/1 (0)    0/2 (0) 0/3 (0)
Ciprofloxacin   0/1 (0)    1/2 (50) 1/3 (33.3)
Meropenem   0/1 (0)    0/2 (0) 0/3 (0)
Cefepime   0/1 (0)    0/2 (0) 0/3 (0)
Cefoxitin   1/1 (100)    0/2 (0) 1/3 (33.3)
Tobramycin   0/1 (0)    0/2 (0) 0/3 (0)
  1. * Oxacillin discs were not available for antimicrobial testing during the period 16/05/2003 – 15/05/2005
Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us